Immune mediated necrotising myopathy (IMNM): management
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Immune mediated necrotising myopathy (IMNM): management. This is myopathic. Fully referenced neurology checklist.
Electromyogram (EMG)
- This is myopathic
- It may show myotonic discharges: especially in statin-induced cases
Muscle biopsy
Locked: subscribe to see this section.
Other investigations
Locked: subscribe to see this section.
Cancer screening: indications
Locked: subscribe to see this section.
Treatment options
Locked: subscribe to see this section.
Synonym
Locked: subscribe to see this section.
References
- Castro C, Gourley M. Diagnosis and treatment of inflammatory myopathy: issues and management. Ther Adv Musculoskel Dis 2012; 4:111-120.
- Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010; 41:185-190.
- Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, Milisenda JC, Grau-Junyent JM, Mammen AL. Classification and management of adult inflammatory myopathies. Lancet Neurol 2018; 17:816-828.
- Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain 2016; 139:2131-2135.
- Kruse RL, Albayda J, Vozniak SO, et al. Therapeutic plasma exchange for the treatment of refractory necrotizing autoimmune myopathy. J Clin Apher 2022; 37:253-262.
- And 2 more. Subscribe to see the full list
